"Levying additional costs beyond [corporates'] normal credit lines is highly undesirable--not least when for some time we will be trying to achieve a recovery in the real economy."

--Sharon Bowles, chairwoman of the European Parliament's Economic and Monetary Affairs Committee, on why corporates should be exempt from pending over-the-counter derivatives regulation in Europe.